Davis L. Temple
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Davis L. Temple.
Progress in Neuro-psychopharmacology & Biological Psychiatry | 1983
Leslie A. Riblet; Arlene S. Eison; Michael S. Eison; R.E. Newton; Duncan P. Taylor; Davis L. Temple
Buspirone HCl (Buspar) is a novel anxiolytic agent unrelated to the benzodiazepines or other psychotherapeutic agents. Animal studies support an anxioselective profile, i.e. relief of anxiety without sedation, muscle relaxation or anticonvulsant activity. Double-blind clinical studies show buspirone to be effective in the treatment of anxiety and anxiety in the presence of depression. The effects of buspirone on psychomotor function, physical dependence and abuse potential tests are similar to those seen with placebo treatments. Mechanism of action studies indicate activity in a variety of neuronal systems.
The American Journal of Medicine | 1986
Arlene S. Eison; Davis L. Temple
Journal of Medicinal Chemistry | 1992
Joseph P Yevich; James S. New; Walter G. Lobeck; Pierre Dextraze; Edith Bernstein; Duncan P. Taylor; Frank D. Yocca; Michael S. Eison; Davis L. Temple
Archive | 1985
Neil Kurtz; Roger E. Newton; Davis L. Temple
Journal of Medicinal Chemistry | 1983
Joseph P Yevich; Davis L. Temple; James S. New; Duncan P. Taylor; Leslie A. Riblet
Journal of Medicinal Chemistry | 1988
James S. New; Joseph P Yevich; Davis L. Temple; New Kb; Gross Sm; Schlemmer Rf; Michael S. Eison; Duncan P. Taylor; Leslie A. Riblet
Archive | 1987
Graham S. Poindexter; Davis L. Temple
Archive | 1995
Valentin K. Gribkoff; Steven I. Dworetzky; Davis L. Temple
Drug Development Research | 1987
Allen W. Gomoll; Davis L. Temple
Archive | 1985
Xina Nair; Davis L. Temple
